These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 19205388

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. 5alpha-reductase inhibitors/finasteride.
    Stoner E.
    Prostate Suppl; 1996; 6():82-7. PubMed ID: 8630236
    [Abstract] [Full Text] [Related]

  • 3. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
    [Abstract] [Full Text] [Related]

  • 4. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G, Rittmaster RS, Klocker H.
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Finasteride (Proscar) for benign prostatic hypertrophy].
    Matzkin H, Chen J, Braf Z.
    Harefuah; 1993 Dec 15; 125(12):453-6, 496. PubMed ID: 7509305
    [Abstract] [Full Text] [Related]

  • 9. [The treatment of patients with benign prostatic hyperplasia with Proscar MSD (finasteride)].
    Stepanov VN, Teodorovich OV, Seregin AV, Kadyrov ZA.
    Urol Nefrol (Mosk); 1995 Dec 15; (5):28-30. PubMed ID: 8571480
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Measurement of T and DHT contents in normal and diseased human prostate tissues].
    Zhang Y, Ye L, Ding Q, Fang Z, Yao M, Shi D.
    Zhonghua Wai Ke Za Zhi; 2000 Jul 15; 38(7):545-7. PubMed ID: 11832106
    [Abstract] [Full Text] [Related]

  • 16. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma.
    Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB.
    Prostate; 2003 Oct 01; 57(2):134-9. PubMed ID: 12949937
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of 5 alpha-reductase inhibition by finasteride on lipoproteins and body composition in males affected by benign prostatic hyperplasia (BPH).
    Denti L, Pasolini G, Cortellini P, Sanfelici L, Benedetti R, Cecchetti A, Ferretti S, Banchini A, Ablondi F, Valenti G.
    J Endocrinol Invest; 1999 Oct 01; 22(10 Suppl):70-1. PubMed ID: 10727053
    [No Abstract] [Full Text] [Related]

  • 19. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM, Vis AN, van Moorselaar RJ, Bui HN, Blankenstein MA, Meuleman EJ, Heijboer AC.
    BJU Int; 2012 Jan 01; 109(2):176-82. PubMed ID: 21992222
    [Abstract] [Full Text] [Related]

  • 20. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
    Thomas LN, Douglas RC, Vessey JP, Gupta R, Fontaine D, Norman RW, Thompson IM, Troyer DA, Rittmaster RS, Lazier CB.
    J Urol; 2003 Nov 01; 170(5):2019-25. PubMed ID: 14532845
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.